DEFA14A: Veru Inc. Postpones Annual Shareholder Meeting Due to Financial Restatement

Veru Inc. has rescheduled its 2024 Annual Meeting of Shareholders to allow investors time to review restated financial statements, expected to be filed by April 15, 2024, due to overestimated research and development expenses.

Summary

• Veru Inc. has postponed its 2024 Annual Meeting of Shareholders, originally scheduled for March 26, 2024.
• The postponement is due to the ongoing restatement of historical financial statements.
• The restatement is expected to be completed and filed no later than April 15, 2024.
• The restatement was triggered by overestimated research and development expenses.
• The company's cash on hand is now expected to last longer than initially stated.
• A new date for the Annual Meeting will be announced after the restated financials are filed.
• Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS.
• The company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin.
• Enobosarm is being developed for muscle preservation in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA and for metastatic breast cancer.
• Sabizabulin is being developed for viral-induced ARDS, but further development is contingent on securing external funding.
• The company also has an FDA-approved commercial product, the FC2 Female Condom.

Sentiment

Score: 5

Explanation: The announcement contains both positive and negative elements. The postponement of the annual meeting and the need for a financial restatement are negative, but the correction of R&D expenses and the progress of enobosarm clinical trials are positive. The sentiment is neutral overall.

Positives

• The company's cash on hand is expected to last longer than initially stated.
• A Phase 2b clinical trial of enobosarm for muscle preservation in obese elderly patients is expected to begin in April 2024.
• Enobosarm has a large safety database, which includes 27 clinical trials involving 1581 men and women dosed with duration of treatment in some patients for up to 3 years.

Negatives

• The company is restating its historical financial statements due to overestimated research and development expenses.
• The Annual Meeting of Shareholders has been postponed.
• Further development of sabizabulin for the treatment of viral-induced ARDS is contingent on securing external funding.

Risks

• The company faces uncertainties related to the completion and timing of the financial restatement.
• The success of the enobosarm clinical trials is not guaranteed.
• The company may not be successful in securing external funding for the development of sabizabulin.
• The company's actual results could differ materially from forward-looking statements due to various risks and uncertainties.

Future Outlook

The company anticipates completing and filing restated financial statements by April 15, 2024, and will subsequently announce a new date for the Annual Meeting of Shareholders. The company also expects to begin a Phase 2b clinical trial of enobosarm in April 2024, with topline results expected by year-end 2024, and topline results of the Phase 2b extension clinical study is expected in calendar Q2 2025.

Industry Context

Veru is operating in the competitive biopharmaceutical industry, focusing on metabolic diseases, oncology, and ARDS. The development of enobosarm for muscle preservation in obese patients receiving GLP-1 RAs aligns with the growing market for weight loss drugs and the need to address muscle loss associated with these treatments. The company's focus on securing external funding for sabizabulin reflects the challenges of developing treatments for viral-induced ARDS.

Comparison to Industry Standards

• The development of enobosarm for muscle preservation in obese patients receiving GLP-1 RAs is similar to efforts by other companies to address muscle loss associated with weight loss drugs.
• Companies like Viking Therapeutics and Regeneron are also developing therapies targeting muscle mass and metabolic disorders.
• The Phase 2b clinical trial of enobosarm is comparable to other mid-stage clinical trials in the obesity and metabolic disease space.
• The company's focus on securing external funding for sabizabulin is a common strategy for companies developing treatments for diseases with uncertain market potential.

Stakeholder Impact

• Shareholders will be impacted by the postponement of the Annual Meeting and the need to review restated financial statements.
• The company's employees may be impacted by the financial restatement and the need to adjust R&D expenses.
• Patients may be impacted by the progress of enobosarm and sabizabulin clinical trials.
• The company's suppliers and creditors may be impacted by the financial restatement and the company's cash position.

Next Steps

• Complete and file the restated financial statements by April 15, 2024.
• Notify shareholders of the new date and time for the Annual Meeting.
• Commence the Phase 2b clinical trial of enobosarm in April 2024.
• Continue seeking external funding for the development of sabizabulin.

Key Dates

Keywords

Veru Inc., Annual Meeting, Shareholders, Financial Restatement, Enobosarm, Sabizabulin, Clinical Trial, Research and Development, Biopharmaceutical, GLP-1 RA, Muscle Preservation, Obesity, ARDS